Scientific evidence indicates that the risk of acquiring a serious pneumococcal infection is greater, in addition to at an early age, in people older than 60 years and in the adult population with certain risk conditions, such as people with chronic processes or diseases that alter the immune response capacity.
Therefore, the Ministry of Health and the Cantabrian Health Service (SCS) will administer the 20-valent conjugate pneumococcal vaccine the adult population aged 60 or over, as well as people with risk factors.
Cantabria thus incorporates the 20-valent conjugate vaccine (VCN20) against infection by pneumococcus (‘streptococcus pneumoniae’), which replaces the one currently used in the adult population, the 23-valent polysaccharide pneumococcal vaccine. This new vaccine provides stronger protection as well as longer immune memory.
People aged 60 or over who have not yet been vaccinated against pneumococcus, as well as people between 18 and 59 who present conditions or medium or high risk factors, may make an appointment with their health center as of May 22 to receive the single-dose regimen.
Broad protection in a single dose
Infection by ‘streptococcus pneumoniae’ produces a wide range of pathologies, such as pneumonia, otitis media, mastoiditis, sinusitis and other common diseases of the upper respiratory tract. In addition, it can produce more serious complications ranging from invasive pneumococcal disease (IPD), such as bacteremic pneumonia, meningitis or sepsis which, although less frequent, cause greater morbidity and mortality.
The vaccine that Cantabria will inoculate includes protection for 20 serotypes of pneumococcusresponsible for 70 percent of hospitalized adult pneumococcal pneumonia cases.
For these purposes, the vaccine is indicated in people with chronic cardiovascular disease, excluding arterial hypertension; chronic respiratory disease, including cystic fibrosis, and asthma that does not require immunosuppressive treatment; chronic neurological disease with difficulties in the management of secretions; chronic and celiac liver disease; Mellitus diabetes; alcoholism; smokers, even if it is a daily cigarette; people who have suffered severe COVID-19, with hospitalization; people institutionalized in nursing homes, regardless of age, and those with a history of invasive pneumococcal disease.
risk groups
Vaccination of adults is also planned, regardless of age, solid organ transplants (TOS) or hematopoietic progenitorss(TPH); with congenital or acquired immunodeficiencies: humoral (excluding selective IgA deficiency), cellular or combined, complement deficiencies and phagocytosis disorders; any malignancy, hematologic, or solid organ; HIV infection; National Kidney Foundation stages 4 and 5 chronic renal failure and nephrotic syndrome; people with chronic diseases susceptible to receiving immunosuppressive treatment, including those with steroids at immunosuppressive doses or with biological agents, such as inflammatory bowel disease, rheumatic diseases, severe asthma, paroxysmal nocturnal haemoglobinuria, haemolytic uraemic syndrome, myasthenia gravis, etc.
are also considered risk people, and therefore susceptible to vaccination, those with anatomical or functional asplenia (splenic dysfunction), including sickle cell disease and other severe hemoglobinopathies; being treated with eculizumab (Soliris), or long-acting derivatives; Down’s Syndrome; cerebrospinal fluid fistula; as well as carriers of cochlear implants or likely to receive it.
You may also like…
2023-05-17 09:43:37
#Cantabria #administer #20valent #conjugate #pneumococcal #vaccine #age
